359 related articles for article (PubMed ID: 33564942)
21. Sodium-glucose cotransporter-2 inhibitors for hypergycemia in phosphoinositide 3-kinase pathway inhibition.
Weintraub MA; Liu D; DeMatteo R; Goncalves MD; Flory JH
Breast Cancer Res Treat; 2024 Jan; 203(1):85-93. PubMed ID: 37704834
[TBL] [Abstract][Full Text] [Related]
22. A Population-Based Study of SGLT2 Inhibitor-Associated Postoperative Diabetic Ketoacidosis in Patients with Type 2 Diabetes.
Lui DTW; Wu T; Au ICH; Liu X; Fung MMH; Lee CH; Fong CHY; Woo YC; Lang BHH; Tan KCB; Wong CKH
Drug Saf; 2023 Jan; 46(1):53-64. PubMed ID: 36289137
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis.
Al-Hindi B; Mohammed MA; Mangantig E; Martini ND
J Am Pharm Assoc (2003); 2024; 64(1):9-26.e6. PubMed ID: 37844733
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
25. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
Khunti K; Aroda VR; Bhatt DL; Bozkurt B; Buse JB; Heerspink HL; Inzucchi SE; Lam CSP; Marx N; McMurray JJV; Solomon SD; Kosiborod MN
Diabetes Obes Metab; 2022 Nov; 24(11):2071-2080. PubMed ID: 35801339
[TBL] [Abstract][Full Text] [Related]
26. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
Douros A; Lix LM; Fralick M; Dell'Aniello S; Shah BR; Ronksley PE; Tremblay É; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ernst P; Filion KB;
Ann Intern Med; 2020 Sep; 173(6):417-425. PubMed ID: 32716707
[TBL] [Abstract][Full Text] [Related]
27. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
Bamgboye AO; Oni IO; Collier A
Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632
[TBL] [Abstract][Full Text] [Related]
28. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence.
Mehta PB; Robinson A; Burkhardt D; Rushakoff RJ
Endocr Pract; 2022 Sep; 28(9):884-888. PubMed ID: 35753675
[TBL] [Abstract][Full Text] [Related]
29. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.
Stougaard EB; Kristensen PL; Kielgast U; Andersen HU; Hamid Y; Gæde PH; Søndergaard E; Dørflinger GH; Fjeldborg KK; Hansen KW; Thomsen HH; Al-Imar TMJ; Røder M; Sridhar VS; Cherney D; Rossing P; Persson F
Diab Vasc Dis Res; 2022; 19(5):14791641221130043. PubMed ID: 36262089
[TBL] [Abstract][Full Text] [Related]
30. SGLT2 Inhibitors May Predispose to Ketoacidosis.
Taylor SI; Blau JE; Rother KI
J Clin Endocrinol Metab; 2015 Aug; 100(8):2849-52. PubMed ID: 26086329
[TBL] [Abstract][Full Text] [Related]
31. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.
Khedr A; Hennawi HA; Khan MK; Eissa A; Mir M; Rauf I; Nitesh J; Surani S; Khan SA
World J Clin Cases; 2023 Aug; 11(24):5700-5709. PubMed ID: 37727728
[TBL] [Abstract][Full Text] [Related]
33. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
[TBL] [Abstract][Full Text] [Related]
34. An audit of the effect of SGLT2 inhibitor cessation in a pre-admission clinic before and after Australian Diabetes Society guidelines.
Fookeerah P; Law H; Ali F; Chatten K; Kim C; Cheung NW
Intern Med J; 2021 Jun; 51(6):980-983. PubMed ID: 34155765
[TBL] [Abstract][Full Text] [Related]
35. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Menghoum N; Oriot P; Hermans MP; Mariage JL
Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
[TBL] [Abstract][Full Text] [Related]
36. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
Taverner S; Eng C; Watson R; George S; Edwards A; Williams DM; Stephens JW
Diabetes Metab Syndr; 2022 Dec; 16(12):102658. PubMed ID: 36371968
[TBL] [Abstract][Full Text] [Related]
37. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.
Papanastasiou L; Glycofridi S; Gravvanis C; Skarakis N; Papadimitriou I; Kanti G; Kapsali C; Kounadi T
Hormones (Athens); 2021 Jun; 20(2):369-376. PubMed ID: 33151508
[TBL] [Abstract][Full Text] [Related]
38. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
39. Performance assessment of different machine learning approaches in predicting diabetic ketoacidosis in adults with type 1 diabetes using electronic health records data.
Li L; Lee CC; Zhou FL; Molony C; Doder Z; Zalmover E; Sharma K; Juhaeri J; Wu C
Pharmacoepidemiol Drug Saf; 2021 May; 30(5):610-618. PubMed ID: 33480091
[TBL] [Abstract][Full Text] [Related]
40. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Fleming N; Hamblin PS; Story D; Ekinci EI
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
